Skip To Main Content

News & Studies Articles

Sort by

Filtera

Återställ
  • News & Studies Articles
How to use PRALUENT<sup>®</sup>?

PRALUENT is available as a unique,¥ once-monthly pen

Prevent the Event

Prevent the Event

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.1

Why Choose Toujeo<sup>®</sup> (Insulin Glargine)

Why Choose Toujeo® (Insulin Glargine)

Fabry disease

Fabry disease

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

How to diagnose Fabry

How to diagnose Fabry

Think Fabry, think timely testing first.

Monitoring disease progression

Monitoring disease progression

Think Fabry, think regular profile-based assessments.

Cardiac involvement in Fabry disease

Cardiac involvement in Fabry disease

Cardiovascular disease is the leading cause of death in Fabry disease patients.1 Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.2,3

Renal involvement in Fabry disease

Renal involvement in Fabry disease

Think Fabry, think renal involvement that may present early in life and could go undetected.

Family screening

Family screening

Think Fabry, think screening at-risk family members.1

When to treat

When to treat

Think Fabry, think early treatment to help slow or prevent life-threatening disease progression.1,2

Sverige satsar på att skydda spädbarn mot RSV med start 10 september – Beyfortus (nirsevimab) finns nu tillgängligt

RSV-prevention med Beyfortus (nirsevimab) – tillgänglig för nyfödda från 10 september

Beyfortus® är den första och enda RSV-immuniseringen designad för alla spädbarn, för skydd mot RSV-sjukdom i de nedre luftvägarna (LRTD).1

Pooled analysis: Interventional and observational studies

Pooled analysis: Interventional and observational studies

A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/ without prior use of glucagon-like peptide-1 receptor agonist therapy.1